Cover Image
市場調查報告書

腦脊髓炎:開發中產品分析

Encephalomyelitis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 271844
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
腦脊髓炎:開發中產品分析 Encephalomyelitis - Pipeline Review, H2 2017
出版日期: 2017年08月16日 內容資訊: 英文 62 Pages
簡介

腦脊髓炎是腦和脊髓的發炎。一般的原因是感染神經組織的病毒。徵兆和症狀有頸椎僵直,頭痛,發燒等。

本報告提供腦脊髓炎的治療藥開發情形調查分析,提供開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腦脊髓炎概要

治療藥的開發

  • 開發中產品的概要
  • 企業開發中的治療藥
  • 大學/機關研究中的治療藥
  • 企業開發中的產品
  • 大學/機關研究中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

腦脊髓炎的治療藥開發企業

  • Aurigene Discovery Technologies Ltd
  • Biovista Inc
  • Grifols SA
  • Hemispherx Biopharma Inc
  • Johnson & Johnson
  • K-Pax Pharmaceuticals Inc
  • Momenta Pharmaceuticals, Inc
  • Philogen SpA

藥物簡介

腦脊髓炎:暫停中的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9613IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H2 2017, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.

Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, IND/CTA Filed and Preclinical stages are 1, 3, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Encephalomyelitis - Overview
    • Encephalomyelitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Encephalomyelitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Encephalomyelitis - Companies Involved in Therapeutics Development
    • Aurigene Discovery Technologies Ltd
    • Biovista Inc
    • Grifols SA
    • Hemispherx Biopharma Inc
    • Johnson & Johnson
    • K-Pax Pharmaceuticals Inc
    • Momenta Pharmaceuticals Inc
    • Philogen SpA
  • Encephalomyelitis - Drug Profiles
    • alpha-1 proteinase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alpha-1 proteinase inhibitor (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FR-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JM-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KPAX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-254 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Preimplantation Factor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PSA-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rintatolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Chronic Fatigue Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetravil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • thymulin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WEHI-345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Encephalomyelitis - Dormant Projects
  • Encephalomyelitis - Product Development Milestones
    • Featured News & Press Releases
      • May 31, 2017: Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities
      • May 31, 2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology
      • Oct 31, 2016: Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen Phase III Trial in Patients with CFS/ME
      • Aug 23, 2016: Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
      • Jul 27, 2016: Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen
      • Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)" in Expert Review of Clinical Pharmacology
      • Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Encephalomyelitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Encephalomyelitis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
  • Encephalomyelitis - Pipeline by Biovista Inc, H2 2017
  • Encephalomyelitis - Pipeline by Grifols SA, H2 2017
  • Encephalomyelitis - Pipeline by Hemispherx Biopharma Inc, H2 2017
  • Encephalomyelitis - Pipeline by Johnson & Johnson, H2 2017
  • Encephalomyelitis - Pipeline by K-Pax Pharmaceuticals Inc, H2 2017
  • Encephalomyelitis - Pipeline by Momenta Pharmaceuticals Inc, H2 2017
  • Encephalomyelitis - Pipeline by Philogen SpA, H2 2017
  • Encephalomyelitis - Dormant Projects, H2 2017
  • Encephalomyelitis - Dormant Projects, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for Encephalomyelitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top